Delving into the Latest Updates on Dioxidin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Hydroxymethylquinoxalindioxyde

Target-

Mechanism-

Therapeutic Areas

Skin and Musculoskeletal DiseasesInfectious Diseases

Active Indication

PyodermaInfectious Diseases

Inactive Indication-

Originator Organization

Valenta Pharmaceuticals JSC

Active Organization

Valenta Pharmaceuticals JSC

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Opened, Multicenter, Randomized, in Parallel Groups Comparative Study to Assess Efficacy and Safety of Dioxidin®, Solution for Topical and External Application 0.025% (Valenta Farm, Russia) and Miramistin®, Solution for Topical Application 0.01% (Infamed K LLC, Russia) in Treatment of Superficial Pyoderma

The study is aimed to:
evaluate the effectiveness of 10-day therapy with Dioxidin® compared with Miramistin® in the treatment of superficial pyoderma,
evaluate the safety and tolerability of 10-day therapy with Dioxidin® compared with Miramistin® for the treatment of superficial pyoderma.

Start Date19 Jul 2022

Sponsor / Collaborator

Valenta Pharmaceuticals JSC

NCT05505097 / CompletedPhase 1

Open Randomized Comparative Crossover Study of the Safety and Pharmacokinetics of Dioxidin, Solution for Topical and External Use, 0.25 mg/ml and Dioxidin, Solution for Infusion and External Use, 5 mg/ml in Healthy Volunteers

The study aimed for:
To study the safety of the drug Dioxidin, solution for topical and external use;
To determine the concentrations of the active substance of the studied drugs Dioxidin, solution for topical and external use, and Dioxidin, solution for infusion and external use in discrete time intervals;
To study pharmacokinetics of the drug Dioxidin, solution for topical and external application;
To determine the absolute bioavailability of the drug Dioxidine, solution for topical and external use.

Start Date04 May 2022

Sponsor / Collaborator

Valenta Pharmaceuticals JSC

100 Clinical Results associated with Dioxidin

Login to view more data

100 Translational Medicine associated with Dioxidin

Login to view more data

100 Patents (Medical) associated with Dioxidin

Login to view more data

23

Literatures (Medical) associated with Dioxidin

01 Jan 2013·Khirurgiia

[Modern opportunities of abdominal sanation during the generalized purulent peritonitis].

Article

Author: Pervova, O V ; Cherdantsev, D V ; Diatlov, V Iu ; Pozdniakov, A A ; Shapkina, V A

Results of the treatment of generalized purulent peritonitis in 30 patients are presented. Based on the analysis of the performance of integrated assessment scales severity of the condition, the dynamics of change of bacterial contamination and microbiological landscape, and analysis of morbidity and mortality proved the effectiveness of intraperitoneal administration of the solution of dioxidin in patients with generalized purulent peritonitis.

01 Jan 2013·Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]

[Dioxidin: antimicrobial activity and prospects of its clinical use at present].

Article

Author: Kostiuk, G V ; Terekhova, L P ; Pkhakadze, T Ia ; Aleksandrova, I A ; Bogomolova, N S ; Rusanova, E V ; Blatun, L A ; Terent'ev, A A ; Piopov, D A ; Anuchina, N M

In vitro activity of dioxidin against pathogens of nosocomial infections and its cytotoxicity were estimated. The study involved 300 isolates from patients with nosocomial infections. The MICs of dioxidin were determined with the method of serial dilutions in broth. The dioxidin cytotoxicity was investigated with the MTI assay to assign the cell culture viability. In concentrations of 2 to 1024 meg/mi dioxidin was active against 279/300 (93%) strains. The drug inhibited the growth of all the gramnegative isolates. The highest activitywas observed against Enterobacteriaceae vs. nonfermenting gramnegative bacteria: the median, minimum and maximum MICs of dioxidin were 12 (4-32) and 32 (16-64) mcg/ml respectively. The dioxidin activity against gramnegative bacteria and fungi was lower. The MIC of dioxidin for 7/70 (10%) staphylococcal isolates, 9/28 (32%) enterococcal isolates and all the Candida isolates was > 1024 mcg/ml. The IC50 of dioxidin was 2.4+/-0.3 mM (low cytotoxicity). The results showed that the use of dioxidin as an antimicrobial for local application was advisable in the treatment of gramnegative bacterial infections provided adequate tissue concentrations were attained.

01 Jan 2004·Khirurgiia

[Prophylaxis of wound infection with immobilized antibacterial drugs].

Article

Author: Men'shikov, D D ; Bolenko, A V ; Titov, G P ; Kuprikov, S V

New drug ambipor that is an immobilized antibacterial agent with local prolonged therapeutic activity was developed for prophylaxis of wound suppuration. In ambipor A drugs gentamicin, dioxidin, kephzol and riphampicin are immobilazed, in iodopor - iodine. Experimental studies on 455 white rats showed that ambipor prevents suppuration, abscess formation around ligatures, improve regeneration and fibrillogenesis. In clinical practice ambipor A and iodopor were used in 562 patients. Rate of suppuration decreased from 11.7 to 2.3% compared with control group of patients.

100 Deals associated with Dioxidin

Login to view more data